153 related articles for article (PubMed ID: 38834568)
1. Sphingosine d18:1 promotes nonalcoholic steatohepatitis by inhibiting macrophage HIF-2α.
Xia J; Chen H; Wang X; Chen W; Lin J; Xu F; Nie Q; Ye C; Zhong B; Zhao M; Yun C; Zeng G; Mao Y; Wen Y; Zhang X; Yan S; Wang X; Sun L; Liu F; Zhong C; Xia P; Jiang C; Rao H; Pang Y
Nat Commun; 2024 Jun; 15(1):4755. PubMed ID: 38834568
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia-inducible factor-2 promotes liver fibrosis in non-alcoholic steatohepatitis liver disease via the NF-κB signalling pathway.
Cai H; Bai Z; Ge RL
Biochem Biophys Res Commun; 2021 Feb; 540():67-74. PubMed ID: 33450482
[TBL] [Abstract][Full Text] [Related]
3. Hepatocyte-Specific Deletion of HIF2α Prevents NASH-Related Liver Carcinogenesis by Decreasing Cancer Cell Proliferation.
Foglia B; Sutti S; Cannito S; Rosso C; Maggiora M; Autelli R; Novo E; Bocca C; Villano G; Ramavath NN; Younes R; Tusa I; Rovida E; Pontisso P; Bugianesi E; Albano E; Parola M
Cell Mol Gastroenterol Hepatol; 2022; 13(2):459-482. PubMed ID: 34655812
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia-inducible factor-2α promotes fibrosis in non-alcoholic fatty liver disease by enhancing glutamine catabolism and inhibiting yes-associated protein phosphorylation in hepatic stellate cells.
Yan R; Cai H; Zhou X; Bao G; Bai Z; Ge RL
Front Endocrinol (Lausanne); 2024; 15():1344971. PubMed ID: 38501098
[TBL] [Abstract][Full Text] [Related]
5. Role of XBP1 in regulating the progression of non-alcoholic steatohepatitis.
Wang Q; Zhou H; Bu Q; Wei S; Li L; Zhou J; Zhou S; Su W; Liu M; Liu Z; Wang M; Lu L
J Hepatol; 2022 Aug; 77(2):312-325. PubMed ID: 35292349
[TBL] [Abstract][Full Text] [Related]
6. Oxygen therapy alleviates hepatic steatosis by inhibiting hypoxia-inducible factor-2α.
Yu L; Wang H; Han X; Liu H; Zhu D; Feng W; Wu J; Bi Y
J Endocrinol; 2020 Jul; 246(1):57-67. PubMed ID: 32369776
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis.
Krenkel O; Puengel T; Govaere O; Abdallah AT; Mossanen JC; Kohlhepp M; Liepelt A; Lefebvre E; Luedde T; Hellerbrand C; Weiskirchen R; Longerich T; Costa IG; Anstee QM; Trautwein C; Tacke F
Hepatology; 2018 Apr; 67(4):1270-1283. PubMed ID: 28940700
[TBL] [Abstract][Full Text] [Related]
8. Protective effect of isochlorogenic acid B on liver fibrosis in non-alcoholic steatohepatitis of mice.
Liu X; Huang K; Niu Z; Mei D; Zhang B
Basic Clin Pharmacol Toxicol; 2019 Feb; 124(2):144-153. PubMed ID: 30180301
[TBL] [Abstract][Full Text] [Related]
9. Growth differentiation factor 15 ameliorates nonalcoholic steatohepatitis and related metabolic disorders in mice.
Kim KH; Kim SH; Han DH; Jo YS; Lee YH; Lee MS
Sci Rep; 2018 May; 8(1):6789. PubMed ID: 29717162
[TBL] [Abstract][Full Text] [Related]
10. CD44 is a key player in non-alcoholic steatohepatitis.
Patouraux S; Rousseau D; Bonnafous S; Lebeaupin C; Luci C; Canivet CM; Schneck AS; Bertola A; Saint-Paul MC; Iannelli A; Gugenheim J; Anty R; Tran A; Bailly-Maitre B; Gual P
J Hepatol; 2017 Aug; 67(2):328-338. PubMed ID: 28323124
[TBL] [Abstract][Full Text] [Related]
11. Dopamine receptor D2 antagonism normalizes profibrotic macrophage-endothelial crosstalk in non-alcoholic steatohepatitis.
Qing J; Ren Y; Zhang Y; Yan M; Zhang H; Wu D; Ma Y; Chen Y; Huang X; Wu Q; Mazhar M; Wang L; Liu J; Ding BS; Cao Z
J Hepatol; 2022 Feb; 76(2):394-406. PubMed ID: 34648896
[TBL] [Abstract][Full Text] [Related]
12. Hypoxia exacerbates nonalcoholic fatty liver disease via the HIF-2α/PPARα pathway.
Chen J; Chen J; Fu H; Li Y; Wang L; Luo S; Lu H
Am J Physiol Endocrinol Metab; 2019 Oct; 317(4):E710-E722. PubMed ID: 31430204
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of sphingosine 1-phosphate signaling ameliorates murine nonalcoholic steatohepatitis.
Mauer AS; Hirsova P; Maiers JL; Shah VH; Malhi H
Am J Physiol Gastrointest Liver Physiol; 2017 Mar; 312(3):G300-G313. PubMed ID: 28039158
[TBL] [Abstract][Full Text] [Related]
14. Myeloid cell deletion of Aryl hydrocarbon Receptor Nuclear Translocator (ARNT) induces non-alcoholic steatohepatitis.
Scott C; Stokes R; Cha KM; Clouston A; Eslam M; Metwally M; Swarbrick MM; George J; Gunton JE
PLoS One; 2019; 14(12):e0225332. PubMed ID: 31800592
[TBL] [Abstract][Full Text] [Related]
15. Hypoxia-inducible factor 2α drives nonalcoholic fatty liver progression by triggering hepatocyte release of histidine-rich glycoprotein.
Morello E; Sutti S; Foglia B; Novo E; Cannito S; Bocca C; Rajsky M; Bruzzì S; Abate ML; Rosso C; Bozzola C; David E; Bugianesi E; Albano E; Parola M
Hepatology; 2018 Jun; 67(6):2196-2214. PubMed ID: 29266399
[TBL] [Abstract][Full Text] [Related]
16. ARNT-dependent HIF-2 transcriptional activity is not sufficient to regulate downstream target genes in neuroblastoma.
Persson CU; von Stedingk K; Fredlund E; Bexell D; Påhlman S; Wigerup C; Mohlin S
Exp Cell Res; 2020 Mar; 388(2):111845. PubMed ID: 31945318
[TBL] [Abstract][Full Text] [Related]
17. A TNFα/Miz1-positive feedback loop inhibits mitophagy in hepatocytes and propagates non-alcoholic steatohepatitis.
Jin K; Shi Y; Zhang H; Zhangyuan G; Wang F; Li S; Chen C; Zhang J; Wang H; Zhang W; Sun B
J Hepatol; 2023 Aug; 79(2):403-416. PubMed ID: 37040844
[TBL] [Abstract][Full Text] [Related]
18. Isorhamnetin Alleviates Steatosis and Fibrosis in Mice with Nonalcoholic Steatohepatitis.
Ganbold M; Owada Y; Ozawa Y; Shimamoto Y; Ferdousi F; Tominaga K; Zheng YW; Ohkohchi N; Isoda H
Sci Rep; 2019 Nov; 9(1):16210. PubMed ID: 31700054
[TBL] [Abstract][Full Text] [Related]
19. Formyl peptide receptor 2 determines sex-specific differences in the progression of nonalcoholic fatty liver disease and steatohepatitis.
Lee C; Kim J; Han J; Oh D; Kim M; Jeong H; Kim TJ; Kim SW; Kim JN; Seo YS; Suzuki A; Kim JH; Jung Y
Nat Commun; 2022 Jan; 13(1):578. PubMed ID: 35102146
[TBL] [Abstract][Full Text] [Related]
20. Iron alters macrophage polarization status and leads to steatohepatitis and fibrogenesis.
Handa P; Thomas S; Morgan-Stevenson V; Maliken BD; Gochanour E; Boukhar S; Yeh MM; Kowdley KV
J Leukoc Biol; 2019 May; 105(5):1015-1026. PubMed ID: 30835899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
